NasdaqGS:NTRABiotechs
Assessing Natera (NTRA) Valuation After AI Oncology Advances And Strong 2025 Growth Guidance
Natera (NTRA) is back in focus after issuing guidance that points to a 39% year over year jump in Q4 revenue, projected 35% full year 2025 revenue growth, and fresh AI driven oncology updates.
See our latest analysis for Natera.
The past year has been eventful for Natera, with AI focused oncology partnerships, new clinical data readouts and expanded prenatal testing all coinciding with a 46.03% one year total shareholder return and a 22.61% 90 day share price return. This suggests momentum...